Michael Chambers & John Ballantyne, Aldevron co-founders

Alde­vron and In­scrip­ta ink man­u­fac­tur­ing deal for CRISPR Type-V nu­cle­ase

A plan to broad­en ac­cess to CRISPR has at­tract­ed a chunk of fund­ing and is now see­ing its wings spread.

Far­go-based DNA and mR­NA pro­duc­er Alde­vron has signed an agree­ment with life sci­ences com­pa­ny In­scrip­ta to man­u­fac­ture and com­mer­cial­ize the Eu­re­ca-V Nu­cle­ase, a wild-type MAD7 CRISPR Type-V nu­cle­ase.

This part­ner­ship will aim to of­fer this nu­cle­ase as a stan­dard re­search-grade and GMP cat­a­log item. Ac­cord­ing to a press re­lease, the pro­duc­tion of Eu­re­ca-V is slat­ed to start in Q3 of 2022. Fi­nan­cial de­tails of the deal were not im­me­di­ate­ly made avail­able to End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.